Business Context and Reporting Period
Company: ANAVEX LIFE SCIENCES CORP.
Filing Type: Form 8-K (Current Report)
Date of Report: June 19, 2009
Reporting Period: Events occurring on June 19, 2009.
The company, incorporated in Nevada with principal offices in Athens, Greece, reported the entry into a material definitive agreement and the unregistered sale of equity securities.
Key Financial Metrics and Capital Activities
This filing details specific financing transactions rather than periodic financial performance metrics (revenue, profit, or cash flow).
- Convertible Loan: $168,000 total principal from two investors.
- Loan Terms: 8% interest rate; maturity date June 19, 2011; unsecured.
- Conversion Price: $2.25 per unit (1 share common stock + 0.5 warrant).
- Warrant Terms (Loan): Exercise price $3.50; 2-year term.
- Private Placement Units: 495,556 units issued at $2.25 per unit.
- Private Placement Proceeds: Approximately $1,115,001 (495,556 units x $2.25).
- Warrant Terms (Placement): 1.125 warrants per unit; exercise price $2.25; 2-year term.
- Use of Proceeds: General working capital.
Material Changes Versus Prior Period
The filing does not provide comparative financial data or prior period metrics. The material change is the immediate increase in liquidity through the $168,000 loan and the issuance of 495,556 equity units.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use the raised funds for general working capital purposes.
Risks and Contingencies:
- Dilution: The issuance of units and the potential conversion of the loan will increase the number of outstanding shares and warrants.
- Regulatory Compliance: Securities were issued to non-U.S. persons in offshore transactions relying on Regulation S and Section 4(2) exemptions of the Securities Act of 1933.
- Debt Obligation: The company has a fixed obligation to repay $168,000 plus interest by June 19, 2011, unless converted.
Investor Verification Checklist
- Verify the total number of outstanding shares and warrants post-transaction to assess dilution impact.
- Confirm the company's current cash position to evaluate the necessity of the $168,000 loan for working capital.
- Review the specific terms of the warrants (exercise price and expiration) to understand future potential equity issuance.
- Check for any subsequent filings regarding the repayment or conversion of the June 2009 loan.